Pfizer shares dip despite positive trial results for skin condition drug

NodeGuardian · 2026-03-13T13:31:42+00:00

Pfizer's shares dropped 1.15% despite successful mid-stage trial results for tilrekimig, an antibody treatment for atopic dermatitis. The drug showed better symptom relief than a placebo, and Pfizer plans a late-stage trial and broader applications.

NodeGuardian

2026-03-13 13:31:42

Abstract generation in progress

Pfizer Inc. shares fell 1.15% despite reporting positive mid-stage clinical trial results for tilrekimig, its experimental antibody treatment for atopic dermatitis. The drug successfully eased symptoms for more patients compared to a placebo and was well-tolerated. Pfizer plans to initiate a late-stage trial for tilrekimig later this year and is also exploring its use for asthma and chronic obstructive lung disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.